PDF(Pubmed)
Abstract：
Photoimmunotherapy is a new treatment modality in which a tumor-targeting monoclonal antibody is combined with a photoactivated dye and a laser is applied to destroy tumor cells. In Japan, insurance reimbursement for this treatment started in January 2021 for unresectable locally advanced or locally recurrent head and neck cancer. We used photoimmunotherapy to treat two patients with recurrent nasopharyngeal squamous cell carcinoma (NPSCC). The first patient was diagnosed with NPSCC (T1N0M0) and treated with definitive radiotherapy, leading complete response. A local recurrence was observed and treated with photoimmunotherapy. Seven months have passed, complete response is archived. The second patient was diagnosed with NPSCC (cT2N1M1). Multimodal therapy led to a complete response for all lesions. A local recurrent lesion appeared, and photoimmunotherapy has been repeatedly performed. The lesion was controlled as a stable disease for about one year. Photoimmunotherapy could be an effective treatment for local recurrence of NPSCC after radiotherapy.
摘要：
光免疫疗法是一种新的治疗方式，其中靶向肿瘤的单克隆抗体与光活化染料结合，并应用激光破坏肿瘤细胞。在日本,这项治疗的保险报销始于2021年1月,用于治疗无法切除的局部晚期或局部复发的头颈癌.我们使用光免疫疗法治疗了两名复发性鼻咽鳞状细胞癌（NPSCC）患者。第一例患者被诊断为NPSCC（T1N0M0），并接受确定性放疗，领先的完整回应。观察到局部复发并用光免疫疗法治疗。七个月过去了,完整的响应已存档。第二名患者被诊断为NPSCC(cT2N1M1)。多模式治疗导致所有病变的完全反应。出现局部复发病变，光免疫疗法已多次进行。病变控制为稳定疾病约一年。光免疫疗法可能是治疗NPSCC放疗后局部复发的有效方法。
